How long does it take for dasatinib to lose its effectiveness after stopping the drug?

There is no fixed answer to the question of how long it will take for dasatinib to lose its effectiveness after stopping the drug, because it is affected by many factors, including individual differences in patients, drug metabolism speed, treatment response before stopping the drug, and monitoring after stopping the drug.

The half-life of dasatinib is approximately4-5 hours, which means that within this time period after administration, the concentration of the drug in the blood will decrease to half of the initial concentration. However, the duration of drug efficacy depends not only on the half-life, but also on factors such as its bioavailability, distribution, metabolism and clearance in the body. Generally, the effective action time of dasatinib in the body can cover approximately 24 hours, so it is recommended to take it at the same time every day to maintain stable blood concentration and sustained therapeutic effect.

After stopping the drug, the concentration of dasatinib in the body will gradually decrease until the effective concentration cannot be detected, at which time the drug effect can be considered to have disappeared.

Different patients have different drug metabolism rates, liver and kidney functions, etc., which will affect the clearance rate of the drug in the body, thus affecting the time it takes for the drug effect to disappear.

If the patient has achieved deep molecular remission and his condition is stable before stopping the drug, he may be able to maintain a certain therapeutic effect for a long time after stopping the drug. Close monitoring after drug discontinuation is critical to assess the time to loss of drug effect. By regularly testing the patient's hematological indicators, BCR-ABL transcript levels, etc., we can learn about changes in the condition and disappearance of drug effects in a timely manner.

There are currently some studies on the maintenance time of dasatinib's efficacy after discontinuation, such as D-STOP, DESTINY and CML1113. These studies are designed to evaluate the treatment response and disease stability of patients at different drug withdrawal time points. However, the results of these studies have not clearly defined a time frame for how long it takes for the drug to lose its effectiveness after discontinuation.